Date: 2016-04-14
Type of information: Series A financing round
Company: Targedys (France)
Investors: Seventure Partners (France) NCI (France) Pontifax (Israel)
Amount: €5.8 million
Funding type: series A financing round
Planned used: TargEDys was incorporated in 2011 by a group of medical science professionals from France, USA, Sweden, Japan, Brazil and Germany. The operational team consists of a synergic team combining scientific, medical, pharmaceutical development and business expertise: Grégory Lambert (CEO), Serguei Fetissov (scientific referent) and Pierre Déchelotte (chairman of the Board and medical referent). Targedys' activity is based on research from Serguei Fetissov and Pierre Déchelotte, who have identified and described the molecular link of the gut-brain axis: proteins from gut bacteria were found to be ‘molecular mimetics’ of peptide hormones involved in the regulation of eating behaviour in the brain and peripheral organs.
TargEDys is dedicated to the modulation of appetite and develops functional food, medical food and pharmaceutical products to harness the microbiome’s ability to regulate appetite and thus maintain or restore weight and metabolic health. Its products target high appetite leading to overweight, and low appetite leading to malnourishment
in elderly people, cachexia and anorexia. The first product will target overweight people. The second product will increase appetite in elderly, cachexic and anorexic patients.
Others: * On April 14, 2016, TargEDys announced a €5.8 million series A financed round based on research from company founders Serguei Fetissov and Pierre Déchelotte, from the UMR INSERM 1073 in the Faculty of Medicine and Pharmacy of Rouen. This round of financing brings together an international syndicate which includes Seventure Partners, Pontifax, a life sciences investor from Israel, and NCI, a regional fund manager stimulating innovation in Normandy.
Therapeutic area: Metabolic diseases
